Design Therapeutics reported a net loss of $20.3 million for the third quarter of 2026, driven by $22.2 million in operating expenses primarily for R&D. The company maintained a strong liquidity position with $208.6 million in cash and investments, which management expects will fund operations for at least 12 months.
Design Therapeutics reported third quarter 2026 financial results, posting a net loss of $20.3 million. The company ended the period with $208.6 million in cash and securities, which it expects will provide a strong financial runway for its clinical-stage GeneTAC programs. Key upcoming milestones include a registrational plan update for DT-216P2 in Q4 2026 and 12-week clinical data in Q1 2027.
“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia. In DM1, our Phase 1 trial of DT-818 is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA. Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”
Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics